What is the official ID of this bill?
The official print number for this legislation is S 562.
Faster Access to Generic Drugs: Ending Delays
This act aims to speed up the market entry of more affordable generic drugs. It introduces new rules that make it harder for pharmaceutical companies to intentionally delay the approval of generics, potentially leading to lower drug prices for citizens and greater choice. The changes are designed to prevent the misuse of legal procedures to block competition.
Key points
Facilitating access to cheaper generic drugs by eliminating unjustified delays in their approval.
Introducing clear criteria to assess whether pharmaceutical company petitions are intended to delay competition.
Enabling referrals to the Federal Trade Commission for companies intentionally delaying generic drug entry.
Requiring exhaustion of administrative remedies before filing civil actions, streamlining legal processes.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.